Trial Profile
Phase II trial of clarithromycin/clofazimine/rifabutin [RHB 104] in patients with Crohn's disease secondary to Mycobacterium avium paratuberculosis infection
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2013
Price :
$35
*
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Crohn's disease; Mycobacterium avium paratuberculosis infections
- Focus Therapeutic Use
- Sponsors RedHill Biopharma
- 16 Sep 2013 Status changed from planning to unconfirmed (trial never initiated).